Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials

Br J Haematol. 2020 Jul;190(2):e95-e97. doi: 10.1111/bjh.16735. Epub 2020 May 13.

Authors

Sariya Wongsaengsak¹, Jonathan Kopel², Tapas R Behera³, Rajshekhar Chakraborty³, Somedeb Ball¹

Affiliations

¹ Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
² School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
³ Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

PMID: 32400886
DOI: 10.1111/bjh.16735

No abstract available

Keywords: adverse effect; carfilzomib; multiple myeloma therapy; pneumonia; prophylaxis; proteasome inhibitor.

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

Aged
Humans
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy
Oligopeptides / adverse effects*
Proteasome Inhibitors / adverse effects*
Randomized Controlled Trials as Topic

Substances

Oligopeptides
Proteasome Inhibitors
carfilzomib